Ozempic Stomach Pain

When Abdominal Pain May Signal a Serious GLP-1 Complication

Last updated: May 29, 2026  |  Covers: Ozempic, Wegovy, Mounjaro, Zepbound  |  Read time: ~10 min

Stomach pain is one of the most frequently reported side effects associated with Ozempic and the broader GLP-1 drug class. That fact alone is not particularly alarming — abdominal discomfort is common in the early weeks of GLP-1 treatment and typically reflects the body’s adjustment to the drug’s gastric-slowing mechanism. For most patients, it improves with time, dietary modification, and gradual dose escalation.

Stomach pain is a common side effect of Ozempic, often caused by delayed stomach emptying and altered digestion. While mild cramps, bloating, and nausea usually subside within 4 to 8 weeks, severe or persistent pain can indicate a serious medical complication. But for a meaningful subset of patients, the stomach pain associated with Ozempic use does not follow that reassuring trajectory. It persists. It worsens with dose increases. It arrives alongside other symptoms — vomiting of undigested food, abdominal distension, inability to eat, severe bloating — that together point toward something more serious than routine adaptation-phase nausea. In some cases, persistent or severe abdominal pain is the presenting symptom of a genuinely dangerous gastrointestinal complication.

This page explains why Ozempic causes stomach pain, what distinguishes ordinary side effects from warning signs of serious complications, the specific conditions that abdominal pain may indicate, and the legal context surrounding these injuries. For background on how GLP-1 drugs work and why their gastrointestinal effects are so predictable, see our GLP-1 drugs — how they work page.

Why Does Ozempic Cause Stomach Pain?

To understand why abdominal pain is such a common complaint among GLP-1 drug users, it helps to understand the mechanism the drug is using to produce its therapeutic effects. Ozempic (semaglutide) works by mimicking the body’s natural glucagon-like peptide-1 hormone, amplifying several of its effects simultaneously — stimulating insulin release, suppressing glucagon, reducing appetite through central nervous system activity, and, critically, slowing the rate at which the stomach empties its contents into the small intestine.

That last effect — delayed gastric emptying, or gastroparesis — is both a therapeutic feature and the primary source of GLP-1-related gastrointestinal side effects. When food leaves the stomach more slowly than normal, several mechanical and physiological consequences follow:

• Food accumulates in the stomach for longer than usual, creating prolonged feelings of fullness and pressure
• The stomach’s muscular walls are under sustained distension, which can produce discomfort and cramping
• Fermentation of retained gastric contents by bacteria contributes to bloating and gas accumulation
• Intestinal transit time increases further downstream, contributing to constipation and lower abdominal discomfort
• The sensory nerves in the gut wall — which are densely distributed and highly sensitive — respond to this abnormal distension and motility with pain signals

For most patients, these effects are moderate and self-limiting. The gastrointestinal system adapts over time, and the degree of gastric slowing tends to stabilize at a level that is tolerable. For others, the slowing does not moderate sufficiently, and the symptoms it produces are severe enough to interfere with nutrition, daily function, and overall health.

Common Side Effect vs. Serious Warning Sign: How to Tell the Difference

One of the most clinically important questions for patients experiencing Ozempic-related abdominal pain is whether what they are feeling reflects the expected adaptation-phase side effects that GLP-1 drugs routinely produce, or whether it represents a warning sign of something that requires medical attention. The distinction is not always immediately obvious, but several features of the pain itself — and of the accompanying symptom pattern — help distinguish between the two.

Abdominal pain that falls within the expected side effect profile of GLP-1 therapy tends to have the following characteristics:

• Appears in the first few weeks of treatment or following a dose increase
• Is mild to moderate in intensity and does not significantly interfere with daily activities
• Improves gradually over days to weeks as the body adapts
• Is accompanied by manageable nausea rather than repeated or forceful vomiting
• Responds to dietary adjustments such as smaller, more frequent meals and reduced fat intake

Pain that falls outside this expected pattern — and that warrants medical evaluation — is more likely to have these features:

• Severe intensity that is disproportionate to what would be expected from routine gastric slowing
• Persistence beyond the typical adaptation window, or worsening rather than improving over time
• Accompanying vomiting that is frequent, forceful, or contains undigested food eaten many hours earlier
• Progressive abdominal distension or visible swelling of the abdomen
• Inability to retain food or fluids, leading to weight loss or dehydration
• Fever, rapid heart rate, or other signs of systemic inflammation
• Pain that radiates to the back — a hallmark of pancreatic involvement

Seek emergency medical attention immediately if your abdominal pain is sudden and severe, is accompanied by vomiting blood or passing black or tarry stools, causes yellowing of the skin or eyes, is associated with fainting or loss of consciousness, or is accompanied by signs of serious dehydration such as inability to urinate, extreme dizziness, or rapid heartbeat.

Serious Gastrointestinal Conditions That Stomach Pain May Indicate

Several medically significant conditions have been linked to GLP-1 drug use and may present with abdominal pain as a primary or prominent symptom. Each carries its own clinical risk profile and its own relevance to the litigation currently pending in federal and state courts. Recognizing the symptom patterns associated with each is important for patients who may be experiencing more than routine GLP-1 side effects.

Gastroparesis

Gastroparesis — literally, stomach paralysis — is the most frequently alleged serious injury in GLP-1 litigation, accounting for approximately 75 percent of the more than 3,600 cases currently consolidated in MDL 3094 in the Eastern District of Pennsylvania. It occurs when the stomach’s ability to contract and propel its contents forward is so severely impaired that food sits unprocessed in the stomach for hours or days. Ozempic’s gastric-slowing mechanism is the same mechanism that, in some patients, progresses from a manageable therapeutic effect to a pathological state. The January 2025 Ozempic label update acknowledged that the drug is “not recommended in patients with severe gastroparesis” — but the label still does not state that Ozempic itself can cause the condition. That omission is central to thousands of pending lawsuits. For a detailed discussion of gastroparesis claims, eligibility standards, and the gastric emptying study requirement established by Judge Marston in August 2025, see our gastroparesis lawsuit page.

Abdominal pain in gastroparesis tends to be diffuse rather than sharply localized, often described as a constant dull ache or pressure in the upper abdomen. It is typically accompanied by early satiety — feeling full after just a few bites — and by nausea and vomiting that is characteristically of undigested food eaten hours earlier. Some patients describe episodes of severe vomiting occurring four, six, or even twelve hours after their last meal.

Ileus

Ileus is a condition in which the intestines cease moving their contents forward without any mechanical obstruction being present — a functional shutdown of intestinal motility rather than a physical blockage. GLP-1 drugs’ motility-slowing effects on the gastrointestinal tract extend beyond the stomach; in some patients, the sluggishness propagates through the small intestine and colon, producing the functional paralysis that characterizes ileus. The condition was formally added to the Ozempic label as an adverse reaction in September 2023, years after patients had begun reporting it. Patients who developed ileus before that label update had no warning that this recognized complication was possible. For a full discussion of ileus claims and their legal significance, see our ileus and bowel obstruction page.

The abdominal pain associated with ileus tends to be crampy and diffuse, accompanied by progressive distension as gas and intestinal contents accumulate behind the dysfunctional segment. A characteristic feature is the inability to pass gas or have a bowel movement despite the sensation of needing to do so. In severe cases, abdominal distension becomes visible and the abdomen may feel taut or drum-like on examination.

Bowel Obstruction

Unlike ileus — which is a functional motility problem — bowel obstruction involves a physical barrier preventing the normal passage of intestinal contents. GLP-1 drugs may contribute to obstruction by dramatically slowing gut motility, allowing contents to become progressively more compacted until they form a blockage. Intestinal obstruction was added to the Ozempic label as an adverse reaction in October 2025, following ileus’s addition in 2023 — another instance of reactive labeling that plaintiffs argue came too late. Complete bowel obstruction is a surgical emergency: untreated, it can produce intestinal ischemia, perforation, and sepsis.

Bowel obstruction typically presents with colicky abdominal pain — cramping that comes in waves rather than being constant — accompanied by nausea, vomiting that may progress to feculent material in severe cases, abdominal distension, and complete inability to pass gas or stool. The onset of fever and continuous rather than colicky pain in a patient with obstruction should prompt immediate emergency evaluation, as these features suggest intestinal ischemia or perforation.

Pancreatitis

Pancreatitis — inflammation of the pancreas — has been associated with GLP-1 receptor agonist use, and its most severe forms are life-threatening. Acute pancreatitis produces one of the most distinctive pain patterns in abdominal medicine: severe, constant epigastric pain that radiates straight through to the back, often described as boring or knife-like, that is worsened by lying flat and partially relieved by leaning forward. It is accompanied by nausea and vomiting, fever, and rapid heart rate. In hemorrhagic or necrotizing forms, which the January 2025 Ozempic label update explicitly acknowledged as documented complications in GLP-1 users, the condition can progress to multi-organ failure. Pancreatitis is a qualifying injury in MDL 3094 and any patient with suspected pancreatitis requires immediate emergency evaluation. Our pancreatitis page covers the condition and its clinical and legal dimensions in detail.

The pain of pancreatitis is qualitatively different from the diffuse cramping of gastroparesis or the colicky pain of obstruction. Patients typically describe it as the worst abdominal pain they have ever experienced, constant rather than episodic, and unrelieved by position changes, antacids, or any measure short of opioid analgesia. Diagnosis is confirmed by elevated serum amylase and lipase levels and, in more severe cases, CT scanning demonstrating pancreatic inflammation.

Severe Gastrointestinal Inflammation

Some patients on GLP-1 medications develop a pattern of severe, diffuse gastrointestinal inflammation that does not fit neatly into the categories above but that produces significant abdominal pain, cramping, diarrhea, and systemic symptoms including fever and fatigue. The clinical picture may resemble acute gastroenteritis, but its temporal association with GLP-1 drug use and its severity distinguish it from ordinary gastrointestinal illness. Persistent symptoms in this pattern warrant gastroenterological evaluation and should not be dismissed as a minor side effect.

Stomach Pain and Dose Escalation

A consistent clinical observation across GLP-1 drug users is that abdominal pain frequently worsens at specific points in the treatment course: when the drug is first initiated and when the dose is increased. This dose-dependence reflects the direct relationship between the magnitude of GLP-1 receptor activation and the degree of gastric slowing the drug produces. Higher doses produce more pronounced delay in gastric emptying, more sustained appetite suppression, and more intense gastrointestinal effects across the board.

Novo Nordisk’s prescribing guidance addresses this by recommending a graduated dose escalation protocol: patients typically begin at the lowest approved dose and titrate upward over a period of months. The rationale is to allow the gastrointestinal system time to adapt at each dose level before the next increase is introduced. In practice, this protocol helps many patients but does not eliminate the dose-escalation pain pattern for all of them. Patients who experience worsening abdominal pain following a dose increase should discuss this with their prescribing physician before proceeding to the next escalation step. In some patients, slower escalation, dose reduction, or medication discontinuation is the appropriate clinical response.

Patients who notice a consistent pattern of worsening stomach pain following each Ozempic dose increase — particularly if that pain is severe, persistent, or accompanied by vomiting — should raise this with their prescriber before continuing dose escalation. This pattern may indicate that the degree of gastric slowing the drug is producing in that individual exceeds what the gastrointestinal system can tolerate.

Can Stomach Pain Continue After Stopping Ozempic?

Yes — and for patients whose abdominal pain is associated with gastroparesis or a significant motility disorder rather than routine adaptation-phase GI effects, this is one of the most clinically and legally important aspects of their experience. Semaglutide has a half-life of approximately seven days, meaning the drug itself clears from the body within four to six weeks of the last dose. Mild gastrointestinal side effects typically resolve within that window.

What the litigation record and adverse event reports have documented, however, is that some patients’ gastric motility does not return to normal after semaglutide clears. The functional impairment to the stomach’s contractile mechanism appears, in a subset of patients, to be more persistent than the drug’s pharmacological presence in the body. Patients have reported ongoing nausea, vomiting, abdominal pain, and inability to eat normally for months — and in some cases indefinitely — after their last Ozempic dose. This post-discontinuation persistence is central to the damages analysis in gastroparesis claims: a condition that outlasts the prescription is by definition an injury with consequences beyond the period of drug exposure.

Patients who continue to experience significant abdominal pain, nausea, or vomiting after stopping an Ozempic or other GLP-1 medication should pursue specialist evaluation rather than waiting for symptoms to resolve. Relevant diagnostic workup includes:

• Gastroenterology consultation with a physician experienced in motility disorders
• Gastric emptying scintigraphy (gastric emptying study) — the definitive test for gastroparesis and now required for GI claims in MDL 3094
• Abdominal imaging including CT scan or ultrasound to evaluate for obstruction or structural abnormality
• Laboratory testing including serum amylase, lipase, metabolic panel, and electrolytes
• A thorough medication history review to establish the temporal relationship between GLP-1 drug use and symptom onset

Ozempic Stomach Pain and the GLP-1 Lawsuits

Abdominal pain occupies a central place in the GLP-1 litigation landscape — both as a presenting symptom and as evidence of the gastrointestinal injuries that form the basis of thousands of pending claims. The lawsuits are not about nausea or routine digestive discomfort. They are about serious, documented injuries — gastroparesis, bowel obstruction, ileus, pancreatitis — that required hospitalization, produced lasting functional impairment, and that plaintiffs allege they were never warned about.

The failure-to-warn theory that underpins GLP-1 litigation examines two questions in relation to stomach pain and related GI injuries: what did Novo Nordisk know, and when did it tell patients? Each label update creates a before-and-after benchmark. Patients who developed ileus before September 2023, when ileus was added to the Ozempic label, had no warning that this risk existed. Patients who developed pancreatitis before January 2025, when explicit pancreatitis language was added, received no label disclosure of that risk. Patients who remain at risk of gastroparesis today are still using a drug whose label acknowledges it is not appropriate for patients who already have severe gastroparesis, but that still does not state that Ozempic itself can cause the condition.

For patients who experienced hospitalizations, emergency care, surgical intervention, or lasting digestive impairment following GLP-1 use, the medical documentation associated with those events is the foundation of any legal claim. Records that typically matter most include prescription history showing which GLP-1 drug was taken and at what doses, emergency department or hospital admission records, gastroenterology specialist consultation notes, imaging results, laboratory values, and surgical records where applicable. For a full discussion of the evidence standards being applied in MDL 3094, including the gastric emptying study requirement for gastroparesis claims, see our GLP-1 litigation eligibility page.

Most GLP-1 lawsuits are brought as individual mass tort claims rather than class actions, which means each plaintiff’s compensation is evaluated on the specific facts and severity of their own case. For an explanation of how the MDL structure works and what it means for individual plaintiffs, see our MDL vs. class action page.

What Patients Should Do

The appropriate response to Ozempic-related stomach pain depends on where on the spectrum from routine side effect to serious complication a patient’s symptoms fall. The following guidance addresses both the medical and practical steps that are most relevant.

For Mild to Moderate Pain in the Early Treatment Period

Patients experiencing abdominal discomfort in the early weeks of Ozempic treatment or following a dose increase should speak with their prescriber about dietary strategies and dose management. Eating smaller, more frequent meals, avoiding high-fat and high-sugar foods, eating slowly, and not lying down immediately after meals are evidence-based approaches to reducing GLP-1-related GI symptoms. If symptoms are interfering with nutrition or quality of life, a discussion with the prescriber about pausing dose escalation or temporarily reducing the dose is appropriate.

For Severe, Persistent, or Worsening Pain

Patients whose abdominal pain is severe, has not improved after the expected adaptation period, is worsening over time, or is accompanied by the symptom patterns described in the serious complications section above should seek medical evaluation promptly. This means contacting their prescribing physician, but in cases of severe or rapidly worsening pain, it means going to an emergency department. Gastroparesis, bowel obstruction, and pancreatitis are all conditions that can deteriorate rapidly and that benefit from early diagnosis and intervention.

Do not self-manage severe or worsening abdominal pain. If your pain is severe, sudden, or accompanied by vomiting blood, black stools, fever, jaundice, or signs of serious dehydration, go to an emergency department immediately. Do not wait to see if symptoms resolve on their own.

For Symptoms That Have Persisted After Stopping Ozempic

Patients who discontinued an Ozempic or other GLP-1 medication and are still experiencing abdominal pain, nausea, vomiting, or digestive dysfunction should pursue formal gastroenterological evaluation. A gastric emptying study is the definitive test for gastroparesis and should be requested specifically if there is any suspicion that the stomach’s motility has been persistently impaired. Do not stop or change any other prescribed medication without medical guidance, as your overall metabolic management may need to be reassessed by your prescriber in light of the GLP-1 discontinuation.

Key Takeaways

For patients, caregivers, and legal professionals navigating Ozempic-related abdominal pain, the following points summarize the essential medical and legal picture:

• Stomach pain is a common and mechanistically predictable consequence of GLP-1 drugs’ gastric-slowing effects, concentrated in the early treatment period and during dose escalation
• For many patients, abdominal discomfort is mild and self-limiting; for others, it is severe, persistent, and may signal a serious complication
• The conditions that serious Ozempic-related stomach pain may indicate include gastroparesis, ileus, bowel obstruction, and pancreatitis — all of which are qualifying injuries in MDL 3094 and all of which were added to the Ozempic label at different points after patients began reporting them
• Pain that is severe, worsening, persistent beyond the adaptation period, or accompanied by vomiting of undigested food, abdominal distension, fever, or radiating back pain warrants prompt medical evaluation
• Some patients report abdominal pain and gastrointestinal dysfunction that persists after stopping the medication — a pattern central to the gastroparesis litigation
• The failure-to-warn claims underpinning GLP-1 litigation are directly relevant to stomach pain: each date a warning was added to the Ozempic label is also the date before which patients had no disclosure of the associated risk
• Patients with documented GI injuries requiring hospitalization or specialist care should preserve all related medical records and consider a legal consultation

Abdominal pain should never be dismissed as an inevitable and acceptable cost of GLP-1 therapy without clinical assessment. The drug’s mechanism makes some degree of GI discomfort predictable — but the conditions that serious and persistent stomach pain may signal are not minor inconveniences. They are potentially serious medical events that deserved timely and complete disclosure to patients, and that are now the subject of litigation across thousands of individual cases.